Procept (PRCT): 50% rise on high volume. Why? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Procept (PRCT): 50% rise on high volume. Why?

PRCT 31.91

+1.9%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Douglas who wrote (265)	10/15/1997 11:09:00 AM
From: Trumptown	of 455

Finally some good news...also new ticker is PRCTD (post 1 for 7). Wednesday October 15 7:15 AM EDT Company Press Release Procept Receives Second Patent for PRO 2000 CAMBRIDGE, Mass.--(BW HealthWire)--Oct. 15, 1997--Procept Inc. (Nasdaq:PRCT - news) announced today that it has been issued Patent 5,677,343 covering its PRO 2000 gel, a topical microbicide it is developing as a chemical barrier to prevent HIV infection. This is the second patent the company has been issued relating to the prevention of HIV infection. ''With two issued patents and several applications pending, we are in the process of building a strong patent position in this inportant area of drug development,'' said Stanley C. Erck president and CEO of Procept. ''Establishing a clear proprietary position in this area is a priority for the company and will assist us in our efforts to attract strong corporate partners.'' PRO 2000 is active against a wide range of HIV strains in vitro, as well as against other sexually transmitted disease pathogens, such as herpes simplex virus type 2, a cause of genital lesions. Clinical studies are ongoing to assess the safety of PRO 2000 gel in women. Based on these results additional safety studies will be conducted in populations at high risk for HIV infection. Procept Inc. is engaged in the discovery and development of small molecule therapeutics for the prevention and treatment of chronic and life-threatening immune system disorders. The company's research is based upon its understanding of critical cell receptors responsible for modulating immune responses. Procept is developing therapeutics for the treatment of arthritis, diabetes, organ transplant rejection and infectious diseases, including AIDS and tuberculosis. Procept was founded in 1985 and is traded on the Nasdaq National Market System under the symbol PRCTD.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next